Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of C-CAR031 in GPC3-positive advanced or recurrent hepatocellular carcinoma
CTR20243113Phase 2Active
- Sponsor
- Cellular Biomedicine Group
- Start
- Oct 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of CT011 in hepatocellular carcinoma (HCC), sponsored by Cellular Biomedicine Group. Started Oct 2024; status: active.
02
Drugs
CT011
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20243113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243113.